A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response. (2002)
- Authors:
- USP affiliated authors: NITA, SUZANE KIOKO ONO - FM ; CARRILHO, FLAIR JOSE - FM ; SILVA, LUIZ CAETANO DA - FM
- Unidade: FM
- Assunto: HEPATITE C
- Language: Inglês
- Imprenta:
- Conference titles: Therapies for viral hepatitits
-
ABNT
SILVA, L. C. da et al. A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response. 2002, Anais.. Boston,: Faculdade de Medicina, Universidade de São Paulo, 2002. . Acesso em: 19 abr. 2024. -
APA
Silva, L. C. da, Nita, S. K. O., Medeiros Filho, J. E. M., Pinho, J. R. R., & Carrilho, F. J. (2002). A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response. In . Boston,: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Silva LC da, Nita SKO, Medeiros Filho JEM, Pinho JRR, Carrilho FJ. A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response. 2002 ;[citado 2024 abr. 19 ] -
Vancouver
Silva LC da, Nita SKO, Medeiros Filho JEM, Pinho JRR, Carrilho FJ. A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response. 2002 ;[citado 2024 abr. 19 ] - High resistance to therapy in cirrhotic patients carrying HCV-RNA genotype 3
- High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3.
- Rapid and profound drop HCV RNA viremia induced by high dose of consensus IFN (CIFN) just before starting pegylated interferon (PEG-IFN) plus ribavirin (RBV) in chronic hepatitits C patients (pts) previously resistant to combined therapy (IFN+RBV): preliminary report
- Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon
- Tratamento da hepatite C
- Rapid and profound drop of HCV RNA viraemia induced by high dose of consensus interferon just before starting pegylated interferon plus ribavirin in chronic hepatitis C patients previously resistant to combined therapy:: preliminary report.
- A prospective study of the prevalence of hepatitis B and C virus co-infection among patients with chronic renal disease under hemodialysis
- Searching for chronic hepatitis B patients in a low prevalence area: role of racial origin
- A phylogenetic study of hepatitis B virus in chronically infected Brazilian patients of Western and Asian descent
- Early clearance kinetics of hepatitis C virus (HCV) in patients with chronic hepatitis C under therapy with pegylated-interferon (PEG-IFN) alpha-2b or consensus-interferon (CIFN) plus ribavirin
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
